China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd.
Healthcare Analytical Testing Services Market Worth $12 6 billion finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report)’s share price fell 7.5% during trading on Wednesday . The stock traded as low as $2.32 and last traded at $2.33. 283,291 shares changed hands during trading, a decline of 71% from the average session volume of 961,310 shares. The stock had previously closed at $2.52. Analyst […]
Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 22,300 shares, an increase of 9.9% from the February 29th total of 20,300 shares. Based on an average trading volume of 107,200 shares, the […]
US Says WuXi Sends Intellectual Property to China: Reuters bloomberg.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bloomberg.com Daily Mail and Mail on Sunday newspapers.